Prostacyclin and PGE1 treatment of pulmonary hypertension (Q39668371)

13 September 2017

1 reference

title

Prostacyclin and PGE1 treatment of pulmonary hypertension (English)

1 reference

13 September 2017

main subject

arterial hypertension

0 references

author name string

Long WA

series ordinal

1

1 reference

13 September 2017

Rubin LJ

series ordinal

2

1 reference

13 September 2017

publication date

1 September 1987

1 reference

The American Review of Respiratory Disease

13 September 2017

published in

1 reference

13 September 2017

volume

136

1 reference

13 September 2017

issue

3

1 reference

13 September 2017

page(s)

773-776

1 reference

An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation

13 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM%2F136.3.773

Comparison of the effects of prostacyclin (PGI2), prostaglandin E1 and D2 on platelet aggregation in different species

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM%2F136.3.773

Haemodynamic changes induced by prostacyclin in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM%2F136.3.773

Vasodilator therapy for primary pulmonary hypertension. Limitations and hazards

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM%2F136.3.773

Pulmonary edema with nifedipine in primary pulmonary hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM%2F136.3.773

Diazoxide in treatment of primary pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM%2F136.3.773

Haemodynamic effects of prostacyclin (PGI2) in pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM%2F136.3.773

Effects of prostaglandin E1 on pulmonary circulation in patients with pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM%2F136.3.773

Vasodilator therapy for right ventricular failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM%2F136.3.773

Comparative effects of captopril and isosorbide dinitrate on pulmonary arteriolar resistance and right ventricular function in patients with severe left ventricular failure: results of a randomized crossover study

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM%2F136.3.773

Effect of prostacyclin on vascular capacity in the dog

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM%2F136.3.773

Cardiocirculatory and myocardial energetic effects of prostaglandin E1 in severe left ventricular failure due to chronic coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM%2F136.3.773

Prostaglandin E1 infusion in unstable angina: effects on anginal frequency and cardiac function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM%2F136.3.773

Fatal Outcome following Nifedipine for Pulmonary Hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM%2F136.3.773

21 January 2018

Identifiers

DOI

10.1164/AJRCCM/136.3.773

1 reference

13 September 2017

1 reference